Autologous Stem Cell Transplantation In Multiple Myeloma: Is It Still The Right Choice? - European Medical Journal

Autologous Stem Cell Transplantation In Multiple Myeloma: Is It Still The Right Choice?

Hematology
Download PDF
Authors:
*Patrizia Tosi
Disclosure:

No potential conflict of interest.

Received:
09.04.14
Accepted:
28.05.14
Citation
EMJ Hema. ;1[1]:99-105.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Autologous stem cell transplantation (ASCT) is considered the standard of care for multiple myeloma patients aged <65 years with no relevant comorbidities. The addition of proteasome inhibitors and/or immunomodulatory drugs has significantly increased the percentage of patients achieving a complete remission after induction therapy, and these results are maintained after high-dose melphalan (Alkeran®), leading to a prolonged disease control. Studies are being carried out in order to evaluate whether short- term consolidation or long-term maintenance therapy can result in disease eradication at the molecular level, thus also increasing patient survival. The efficacy of these new drugs has raised the issue of deferring the transplant after achieving a second response upon relapse. Another controversial point is the optimal treatment strategy for high-risk patients, that do not benefit from ASCT, and for whom the efficacy of new drugs is still matter of debate.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now